NuCana (NASDAQ:NCNA) Announces Quarterly Earnings Results, Beats Expectations By $2.11 EPS

NuCana (NASDAQ:NCNA) posted its earnings results on Thursday. The company reported ($0.32) EPS for the quarter, topping the consensus estimate of ($2.43) by $2.11, Zacks reports.

NuCana Stock Performance

NuCana stock traded down $0.01 during midday trading on Friday, hitting $0.80. 2,357 shares of the company were exchanged, compared to its average volume of 419,954. The firm has a market capitalization of $2.11 million, a PE ratio of -0.08 and a beta of 0.89. NuCana has a fifty-two week low of $0.75 and a fifty-two week high of $10.79. The business has a fifty day simple moving average of $0.97 and a two-hundred day simple moving average of $1.56.

About NuCana

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company, through its technology, is developing ProTides medicines to overcome the limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells.